Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Lin Gui, Keshu Zhou, Ting Liu, Yan Qin, Hongmei Jing, Wenyu Li, Yajun Li, Wenrong Huang, Zhen Wang, Xiuhua Sun, Quan Li, Faming Zhang, Henry Li, Lei Zhang, Peng Sun, Xinbao Gao, Yuankai Shi

Blood (2024) 144 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2024-194771

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Lijun Mu, Hai Lin, Hebing Zhou, Hong-xia Shi, Jinghua Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2024-201204

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax， and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS - a Multicenter, Single Arm, Prospective Clinical Study

Lina Xing, Zijing Guo, Chen Huang, Hongmei Jing, Shukai Qiao

Blood (2024) 144 (Supplement 1): 6057.

https://doi.org/10.1182/blood-2024-201929

Published: 2024

Journal Articles

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

Yingtong Chen, Ping Yang, Weilong Zhang, Jing Wang, Shuang Gao, Yuan Yang, Shuozi Liu, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2024-205492

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study

Chong Wei, Shengyu Zhou, Shuangnian Xu, Hongmei Jing, Hui Liu, Wei Zhang, Daobin Zhou

Blood (2024) 144 (Supplement 1): 1691.

https://doi.org/10.1182/blood-2024-209576

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R 2 ) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

Wei Wang, Xu Zhang, Qihui Li, Hua Yin, Xiubin Xiao, Jian Li, Wenrong Huang, Hongmei Jing, Yan Zhang

Blood (2024) 144 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2024-198294

Published: 2024

Journal Articles

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Yuankai Shi, Jianliang Yang, Yongping Song, Keshu Zhou, Zhiming Li, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Li Yu, Wei Meng, Qiying Lu, Wenzhi Tian

Blood (2024) 144 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2024-200499

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Blood (2024) 144 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2024-201978

Published: 2024

Journal Articles

Prognostic Significance of POD24 and Monoclonal Paraproteinemia in Extranodal MZL

Lingli Wang, Jinjie Gao, Wei Wan, Fei Dong, Jing Wang, Weilong Zhang, Ping Yang, Lan Ma, Wei Zhao, Jijun Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6340.

https://doi.org/10.1182/blood-2024-205570

Published: 2024

Journal Articles

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Ping Yang, Chunyuan Li, Jinjie Gao, Yuan Yang, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6339.

https://doi.org/10.1182/blood-2024-205068

Published: 2024

Journal Articles

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience

Ping Yang, Chunyuan Li, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6338.

https://doi.org/10.1182/blood-2024-205042

Published: 2024

Journal Articles

Central Nervous System Involvement in Mantle Cell Lymphoma: Clinical Features, Prognostic Factors and Outcomes from Multi-Centers in China

Ping Yang, Chunyuan Li, Yuan Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Yingtong Chen, Xiaoyu Hao, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6337.

https://doi.org/10.1182/blood-2024-204938

Published: 2024

Journal Articles

Genetic Characteristics of Patients Aged ≥80 Years with Diffuse Large B-Cell Lymphoma

Xiaoya Yun, Jiefei Bai, Ru Feng, Hongmei Jing, Hui Liu

Blood (2024) 144 (Supplement 1): 6228.

https://doi.org/10.1182/blood-2024-207720

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

Polatuzumab Vedotin Plus Anti-CD20 Monoclonal Antibody and Dexamethasone in Previously Untreated Very Old/Frail Patients with Diffuse Large B-Cell Lymphoma

Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Weidong Ding, Xiaoxuan Xue, Haoyu Qin, Hongmei Jing, Hui Liu

Blood (2024) 144 (Supplement 1): 6521.

https://doi.org/10.1182/blood-2024-203031

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor

Junyuan Qi, Bo Jiang, Wei Yang, Xudong Wei, Hongmei Jing, Yongping Song, Andrea Wang-Gillam, Yuli Ding, Chao Bi, Ting Zhang

Blood (2024) 144 (Supplement 1): 4567.

https://doi.org/10.1182/blood-2024-209977

Published: 2024

Journal Articles

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Gang An, Zhongxia Huang, Aibin Liang, Baijun Fang, Hongmei Jing, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2024-206742

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax， and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS - a Multicenter, Single Arm, Prospective Clinical Study

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R 2 ) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Prognostic Significance of POD24 and Monoclonal Paraproteinemia in Extranodal MZL

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience

Central Nervous System Involvement in Mantle Cell Lymphoma: Clinical Features, Prognostic Factors and Outcomes from Multi-Centers in China

Genetic Characteristics of Patients Aged ≥80 Years with Diffuse Large B-Cell Lymphoma

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Polatuzumab Vedotin Plus Anti-CD20 Monoclonal Antibody and Dexamethasone in Previously Untreated Very Old/Frail Patients with Diffuse Large B-Cell Lymphoma

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only